arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

COGNITION THERAPEUTICS INC

CGTX

$0.63 ▼ -0.05 (-6.97%) at close

7 Visible periods

19 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

COGNITION THERAPEUTICS INC faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $45.8M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -110.2% ↗

FCF / Share $-0.34 ↗

Trailing P/E —

Price / Book 1.6x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-23.49M

↑ +30.9% —

FCF / Share Free cash flow per share

$-0.34

↑ +52.9% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
EPS Growth YoY (%)	62.8% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	0.0% Caution ↓ Caution Declining Year-over-year change in earnings per share Optimal: > 10%	5.5% Fair ↓ Fair Declining Year-over-year change in earnings per share Optimal: > 10%	70.9% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	86.8% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	30.9% Excellent ↑ Excellent Improving Year-over-year change in net income	-31.7% Weak ↑ Weak Improving Year-over-year change in net income	-20.5% Weak ↑ Weak Improving Year-over-year change in net income	-82.6% Weak Weak Year-over-year change in net income	-49.5% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	52.9% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-33.2% Weak ↓ Weak Declining Year-over-year change in free cash flow	32.0% Excellent ↓ Excellent Declining Year-over-year change in free cash flow	-12.3% Weak Weak Year-over-year change in free cash flow	89.6% Excellent Excellent Year-over-year change in free cash flow	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
FCF / Net Income (x)	1.05x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.84x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.63x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.31x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.44x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-110.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-227.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-163.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-85.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-44.1% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	20.2% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-98.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-178.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-144.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-86.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-48.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	-244.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-68.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-557%)	-181.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1308%)	-105.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-802%)	-53.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-454%)	-22.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-252%)	11.5% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-23%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Interest Coverage (x)	—	—	-1878.67x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-1555.39x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-32.02x Weak Weak Operating income divided by interest expense Optimal: > 5x	-9.90x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-36.81M	$-25.01M	$-29.92M	$-41.56M	$-54.72M	$-5.19M	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Basic EPS, GAAP (USD)	$-0.32	$-0.86	$-0.86	$-0.91	$-3.13	$-23.76	—
Free Cash Flow per Share (USD)	$-0.34	$-0.72	$-0.54	$-0.79	$-0.70	$-6.78	—
Book Value per Share (USD)	$0.39	$0.31	$0.76	$1.39	$2.31	$-126.55	—
Tangible Book Value per Share (USD)	$0.39	$0.31	$0.76	$1.39	$2.31	$-126.55	—
Basic Weighted Avg Shares (shares)	72.77M	39.73M	30.03M	23.64M	5.19M	508,112	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$34.07M	$18.41M	$24.05M	$39.85M	$51.13M	$3.66M	—
Total Equity (USD)	$34.27M	$18.75M	$24.47M	$40.25M	$51.27M	$-68.18M	$-58.42M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Depreciation Expense (USD)	$36.00K	$107.00K	$96.00K	$83.00K	$93.00K	$98.00K	—
Net Income, GAAP (USD)	$-23.49M	$-33.97M	$-25.79M	$-21.40M	$-11.72M	$-7.84M	—
Operating Cash Flow (USD)	$-24.59M	$-28.47M	$-16.02M	$-18.53M	$-3.63M	$-3.43M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 7 years · 27 quarters

COGNITION THERAPEUTICS INC

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CGTX with peers